TQx - Modular Target Cell-specific Modification Platform Technology

A major problem with current autologous cell therapeutics is their complex production.

Each therapeutic product is manufactured individually for individual patients in special GMP cleanroom facilities - which takes several weeks. On the other hand, generalized in vivo gene therapy is lacking the required high degree of target cell specificity as a prerequisite for the generation of highly effective and safe cellular medicines.

Patients are suffering from an extremely high emotional and physical toll.

TQx is shifting the less scalable, lengthy and cost-intensive "classical" pharmaceutical production of cell therapeutics to a highly automated and ultra-fast gene therapy approach, without abandoning the advantages of autologous cell therapy.

Our ultra-fast process brings the cell therapy directly to the patient instead of producing it under conventional conditions in centralized facilities with the aim of significantly simpler logistics and cost reductions. As a result, the TQx process opens opportunities for the treatment of previously unaddressed indications such as (rare) autoimmune diseases and cancer.

TQx is making cell and gene therapy broadly accessible in order to address the medical needs of many patients.